Conatus Pharmaceuticals (CNAT) Bullish Stance Reiterated at Roth Capital Following Data
Tweet Send to a Friend
Roth Capital analyst Elemer Piros reiterated a Buy rating and $15 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
